Shielding lipids Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied under model designations SL-PG-API-OI for oral solid dose and SL-PG-API-INF for injectable manufacturing. The lipid matrix is hydrogenated and compendial-grade, with acid value ≤ 1.0 mg KOH/g, peroxide value ≤ 2.0 meq O₂/kg, iodine value ≤ 1.0 g I₂/100 g, water content ≤ 0.5% by Karl Fischer titration, and residual solvent levels controlled under USP <467> and Ph. Eur. 5.4. Elemental impurities are tested under ICH Q3D Option 1 for both oral and parenteral exposure limits. Manufacturing is conducted under FDA 21 CFR 210/211 cGMP in an ISO 14644-1 Class 8 environment; the injectable grade is further processed in a Class 5 area. Oral-grade particle size is D90 ≤ 355 µm, while injectable-grade D90 is ≤ 200 µm. The product is supplied in double polyethylene bags under nitrogen overlay in fibre drums.

For tablet manufacturing, the oral grade is melted in a jacketed high-shear granulator at 55–65°C and introduced into a powder bed at impeller tip speed 3–5 m/s with chopper speed 1,500–3,000 rpm. The granulation is transferred to a fluid bed dryer with inlet air 30–40°C and dew point ≤ -20°C to prevent surface bloom. Cooling through the crystallization zone 45–50°C at 0.5–1.0°C/min favours the stable β-form; differential scanning calorimetry at 10°C/min under nitrogen 50 mL/min should display a single endotherm onset 60°C and peak 62–65°C. X-ray powder diffraction using Cu Kα radiation at 40 kV/40 mA should show β-form reflections at 2θ 19.2° and 23.4°; α-form reflections at 21.0° should be absent after controlled cooling. Tablets containing 10–30 wt% lipid in dry granulated blends are compressed on a rotary tablet press at 8–12 kN main compression force, 30–60 rpm turret speed, and dwell 20–35 ms; precompression at 2–4 kN is recommended to limit lamination. Direct compression as a sole filler is not recommended because punch filming and sticking occur above 40 wt% lipid load. At 20 wt% lipid, compact tensile strength is 1.5–2.5 MPa with ejection force 300–500 N; magnesium stearate at 0.5 wt% blended for 3 min may reduce tensile strength by 10–20%, while sodium stearyl fumarate at 1.0 wt% is an alternative when prolonged mixing is required.

What Distinguishes This Lipid from Compendial Glyceryl Behenate in High-Shear Granulation?

In high-shear granulation, the controlled hydroxyl value ≤ 20 mg KOH/g of the shielding lipid reduces melt viscosity and soap formation compared with compendial glyceryl behenate, where hydroxyl value can range from 20–60 mg KOH/g. Acid value is maintained below 1.0 mg KOH/g rather than the common glyceryl behenate upper limit of 4.0 mg KOH/g, decreasing free fatty acid-mediated degradation of acid-labile APIs. Peroxide value is reduced to ≤ 2.0 meq O₂/kg, whereas compendial glyceryl behenate may carry ≤ 5.0 meq O₂/kg; this difference is critical for oxidation-sensitive compounds such as retinoids, corticosteroids, and polyunsaturated drug candidates. Compared with PEGylated lipids, the material lacks polyoxyethylene chains and therefore avoids PEG crystallinity and ethylene oxide residue concerns in injectable formulations. Compared with hydrogenated phospholipids, the higher melting range 55–65°C versus phospholipid transition near 45–55°C imparts lower water absorption and slower hydrolytic degradation in aqueous suspension at 25°C and 40% RH.

Capsule and granule processing employs the oral grade after milling under nitrogen to limit amorphous surface oxidation. The milled material is sieved through 1.0 mm and combined with colloidal silicon dioxide 0.5–1.0 wt% as glidant. In hard capsules, a semi-solid fill containing 10–30 wt% lipid in medium-chain triglycerides or glyceryl monocaprylate is prepared at 60–65°C and filled at 0.6–1.2 g/min per nozzle. The molten lipid matrix is degassed at 65–70°C under ≤ 50 mbar for 15 min before filling into hard gelatin or HPMC capsules; viscosity at 65°C is 0.8–1.5 Pa·s. For granule sachet dosage forms, lipid granules are sieved through 1.0 mm and blended with glidant; granule hardness is 1–3 N and friability is ≤ 0.5%. In vitro disintegration of the lipid matrix is evaluated under USP <711> Apparatus 1 at 100 rpm; lipid-based formulations may require surfactant addition to the dissolution medium, but no universal medium is prescribed in the product monograph.

Injectable lipid nanoparticle preparation begins with combination of the injectable grade and an aqueous surfactant phase using a high-shear rotor-stator at 15,000–20,000 rpm for 5–10 min. The coarse dispersion is passed through a high-pressure homogenizer at 20,000–30,000 psi for 3–5 cycles using a Y-type interaction chamber. The resulting lipid nanoparticle dispersion should exhibit Z-average diameter 80–120 nm and polydispersity index ≤ 0.15 by dynamic light scattering at 25°C and backscatter angle 173°. If solvent-based processing is used, rotary evaporation at 40°C under ≤ 50 mbar removes residual acetone. The product is not intended for terminal sterile filtration at 0.2 µm after nanoparticle formation; aseptic processing requires filtration of the aqueous phase through 0.2 µm filters before homogenization and handling in an ISO 14644-1 Class 5 environment. For oral liquid suspensions, hot-melt dispersion into cold aqueous phase at 2–8°C produces solidified lipid microparticles with D50 10–30 µm; suspension viscosity at 25°C is 50–200 mPa·s at 10 wt% solids, measured with a rotational viscometer at 50 s⁻¹. Published long-term biodistribution data for this specific configuration are limited; formulation-specific stability and compatibility studies are required before clinical use.

Residual Solvent, Elemental Impurity, and Endotoxin Control for Parenteral Use

Residual solvent removal for the injectable grade is performed at 40°C under vacuum ≤ 10 mbar for 12 h; the resulting acetone content is ≤ 50 ppm and isopropanol content is ≤ 100 ppm, consistent with ICH Q3C Class 2 limits for parenteral administration. Endotoxin is controlled at ≤ 0.25 EU/mg by depyrogenation of contact surfaces at 250°C for 30 min and by use of Water for Injection in all processing steps. Elemental impurity testing by ICP-MS under ICH Q3D Option 1 is reported against parenteral daily exposure limits based on a maximum daily dose of 10 g; this yields Class 1 limits of Cd ≤ 0.2 µg/day, Pb ≤ 0.5 µg/day, As ≤ 1.5 µg/day, and Hg ≤ 0.3 µg/day. The product should not be combined with cationic lipids at high molar ratios without pre-screening for electrostatic precipitate formation; the low acid value reduces anionic charge density, but complexation with multivalent counterions can occur in buffered media. The injectable grade is not suitable for terminal autoclaving if the formulation contains oxidation-sensitive co-lipids, because autoclave heat transfer can accelerate peroxide formation in the aqueous phase.

When Lipid Melt Granulation Replaces Solvent-Based Granulation for Moisture-Sensitive APIs

When aqueous or solvent-based granulation is not feasible because the API undergoes hydrolysis, the lipid is melted and used as binder in a twin-screw extruder with L/D 25:1, barrel temperature profile 40–65°C, screw speed 100–200 rpm, and feed rate 5–10 kg/h. The drug-lipid extrudate is spheronized at 500–800 rpm for 60–120 s, yielding granules with hardness 1–3 N and friability ≤ 0.5%. This process avoids residual solvent but is limited to APIs stable at 65°C for 15–30 min; thermolabile compounds require a non-thermal granulation route. The lipid should not be combined with amine-based additives under prolonged heating because free fatty acid traces, although reduced, can undergo amide formation and alter release kinetics. On production-scale equipment, the primary processing bottleneck occurs when fluid bed dryer inlet dew point exceeds -10°C; the granules become sticky and form agglomerates larger than 1.4 mm, requiring re-milling and possible loss of the β-form. Shelf-life assignment under ICH Q1A(R2) long-term storage at 25°C/60% RH and intermediate storage at 30°C/65% RH requires that peroxide value in unopened drums not increase by more than 1.0 meq O₂/kg over 24 months.